Azaindazole Compounds Inhibiting Wnt Pathway Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with aberrant Wnt signaling, such as cancer and other diseases, lack effective inhibitors to modulate cellular events and correct genetic disorders caused by mutations in Wnt pathway components.
Innovation Solution
Development of azaindazole compounds and their salts or analogs that act as Wnt pathway inhibitors, specifically contacting cells with these compounds to antagonize Wnt activity and treat diseases characterized by aberrant growth states or genetic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders associated with aberrant Wnt signaling, then existing therapeutic options are limited, but effective inhibition of Wnt pathway activity cannot be achieved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of Wnt pathway inhibitors. Specifically, the invention describes compounds with specific molecular structures (Formula I) where substituents R1-R8 can be varied to optimize binding affinity and biological activity against Wnt pathway components, thereby achieving effective inhibition where previous treatments failed
Solution Approach 2:
The patent employs composite materials by creating complex heterocyclic compounds that combine multiple functional groups and structural elements. The compounds in Formula I integrate various heteroaryl and heterocyclyl groups with specific substituent patterns, forming composite molecular structures that effectively inhibit Wnt pathway activity and address the limitations of existing single-agent treatments
2Adaptability or versatility
If azaindazole compounds are developed to inhibit Wnt pathway activity, then therapeutic options for Wnt-related diseases are expanded, but the complexity of drug development increases
Solution Approach 1:
The patent applies segmentation by dividing the complex Wnt pathway inhibition task into manageable molecular components. The core azaindazole structure (Formula I) serves as a foundational scaffold that can be systematically modified with different heteroaryl and heterocyclyl substituents (R1-R8), allowing researchers to optimize activity against specific Wnt pathway targets while maintaining a consistent core structure
Solution Approach 2:
The patent demonstrates universality through the design of compounds in Formula I that can potentially address multiple Wnt-related diseases through a single molecular platform. The versatile substituent options (various heteroaryl and heterocyclyl groups with different properties) allow the same core structure to be adapted for treating cancers, fibrotic disorders, and neurological conditions, reducing the need for entirely separate drug development programs
Data Source
AI summary
Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.